Takeda wins approval for new blood pressure med; Seattle Genetics files for brentuximab; Shire responds to the FDA;

@FierceBiotech: FDA hands Protalix a CRL for Gaucher's disease drug. Report | Follow @FierceBiotech

@JohnCFierce: Biotech and pharma boundaries will continue to blur. | Follow @JohnCFierce 

> The FDA has approved Takeda's new drug for high blood pressure. Edarbi tablets will enter a crowded field of blood pressure drugs, but Takeda hopes to carve out a niche for itself with data on 24-hour blood pressure results. Story

> As expected, Seattle Genetics has submitted its BLA for brentuximab in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma. Seattle Genetic release

> Shire has responded to the FDA's rejection of Firazyr for the treatment of HAE. Story

> Recruitment specialist ICTS has combined social media, a website and keyword ads in the start-up campaign for a client's rheumatology study. The digital combination, the service provider says, yielded a viral Internet marketing effect that shortened the enrollment timeline. Report

And Finally... After studying 120,000 older people over a decade, Dutch investigators have concluded that there's no evidence dairy intake--despite the fat--shortens lives. Report